JP2011529691A - 腫瘍動態を評価するための循環変異型ｄｎａ - Google Patents

腫瘍動態を評価するための循環変異型ｄｎａ Download PDF

Info

Publication number
JP2011529691A
JP2011529691A JP2011521359A JP2011521359A JP2011529691A JP 2011529691 A JP2011529691 A JP 2011529691A JP 2011521359 A JP2011521359 A JP 2011521359A JP 2011521359 A JP2011521359 A JP 2011521359A JP 2011529691 A JP2011529691 A JP 2011529691A
Authority
JP
Japan
Prior art keywords
dna
mutation
tumor
gene
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011521359A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011529691A5 (enExample
Inventor
フランク ディール
ルイス ディアス
ケネス ダブリュ． キンズラー
バート ヴォゲルステイン
カースティン シュミット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41610753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2011529691(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2011529691A publication Critical patent/JP2011529691A/ja
Publication of JP2011529691A5 publication Critical patent/JP2011529691A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/197—Modifications characterised by incorporating a spacer/coupling moiety
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/131—Allele specific probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2549/00—Reactions characterised by the features used to influence the efficiency or specificity
    • C12Q2549/10—Reactions characterised by the features used to influence the efficiency or specificity the purpose being that of reducing false positive or false negative signals
    • C12Q2549/119—Reactions characterised by the features used to influence the efficiency or specificity the purpose being that of reducing false positive or false negative signals using nested primers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2011521359A 2008-07-31 2009-07-31 腫瘍動態を評価するための循環変異型ｄｎａ Pending JP2011529691A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8517508P 2008-07-31 2008-07-31
US61/085,175 2008-07-31
US12/512,585 2009-07-30
US12/512,585 US20100041048A1 (en) 2008-07-31 2009-07-30 Circulating Mutant DNA to Assess Tumor Dynamics
PCT/US2009/052436 WO2010014920A1 (en) 2008-07-31 2009-07-31 Circulating mutant dna to assess tumor dynamics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015231649A Division JP2016104010A (ja) 2008-07-31 2015-11-27 腫瘍動態を評価するための循環変異型ｄｎａ

Publications (2)

Publication Number Publication Date
JP2011529691A true JP2011529691A (ja) 2011-12-15
JP2011529691A5 JP2011529691A5 (enExample) 2012-08-30

Family

ID=41610753

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011521359A Pending JP2011529691A (ja) 2008-07-31 2009-07-31 腫瘍動態を評価するための循環変異型ｄｎａ
JP2015231649A Pending JP2016104010A (ja) 2008-07-31 2015-11-27 腫瘍動態を評価するための循環変異型ｄｎａ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015231649A Pending JP2016104010A (ja) 2008-07-31 2015-11-27 腫瘍動態を評価するための循環変異型ｄｎａ

Country Status (5)

Country Link
US (4) US20100041048A1 (enExample)
EP (1) EP2315849B1 (enExample)
JP (2) JP2011529691A (enExample)
CA (1) CA2732623C (enExample)
WO (1) WO2010014920A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016060227A1 (ja) * 2014-10-17 2016-04-21 東洋鋼鈑株式会社 Ｂｃｒ－ａｂｌ阻害剤耐性関連変異の検出方法及びこれを用いたｂｃｒ－ａｂｌ阻害剤耐性を予測するためのデータ取得方法
JP2016104010A (ja) * 2008-07-31 2016-06-09 ザ ジョンズ ホプキンス ユニバーシティー 腫瘍動態を評価するための循環変異型ｄｎａ
WO2017014177A1 (ja) * 2015-07-17 2017-01-26 凸版印刷株式会社 健康状態の評価方法及び抗がん剤に対する長期奏功性の予測方法
JP2018522550A (ja) * 2015-06-23 2018-08-16 ナショナル キャンサー センター 導電性高分子を利用したセルフリーｄｎａ検出用構造体およびその用途
WO2020026776A1 (ja) 2018-07-31 2020-02-06 学校法人 岩手医科大学 がんの診断のためのプローブ／プライマーライブラリー
WO2024203348A1 (ja) * 2023-03-31 2024-10-03 ソニーグループ株式会社 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005009324D1 (de) 2005-04-06 2008-10-09 Maurice Stroun Methode zur Krebsdiagnose mittels Nachweis von DNA und RNA im Kreislauf
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
JP2012511927A (ja) 2008-12-17 2012-05-31 ライフ テクノロジーズ コーポレーション 対立遺伝子変種を検出するための方法、組成物、およびキット
EP3249053A1 (en) 2009-03-27 2017-11-29 Life Technologies Corporation Methods, compositions, and kits for detecting allelic variants
EP2536854B1 (en) * 2010-02-18 2017-07-19 The Johns Hopkins University Personalized tumor biomarkers
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
CA3207599A1 (en) 2010-05-18 2011-11-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
KR20130113447A (ko) 2010-09-24 2013-10-15 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 고정된 프라이머들을 이용하여 표적 dna의 직접적인 캡쳐, 증폭 및 서열화
SG190344A1 (en) 2010-11-30 2013-06-28 Univ Hong Kong Chinese Detection of genetic or molecular aberrations associated with cancer
BR112013020220B1 (pt) 2011-02-09 2020-03-17 Natera, Inc. Método para determinar o estado de ploidia de um cromossomo em um feto em gestação
DK3246416T3 (da) 2011-04-15 2024-09-02 Univ Johns Hopkins Sikkert sekventeringssystem
JP2013081450A (ja) * 2011-09-27 2013-05-09 Arkray Inc 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用試薬キット
WO2013083810A1 (en) * 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
EP2814959B1 (en) * 2012-02-17 2018-01-17 Fred Hutchinson Cancer Research Center Compositions and methods for accurately identifying mutations
US11261494B2 (en) 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
WO2014004726A1 (en) * 2012-06-26 2014-01-03 Caifu Chen Methods, compositions and kits for the diagnosis, prognosis and monitoring of cancer
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
KR102393608B1 (ko) 2012-09-04 2022-05-03 가던트 헬쓰, 인크. 희귀 돌연변이 및 카피수 변이를 검출하기 위한 시스템 및 방법
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
EP2912196B1 (en) 2012-10-26 2018-08-08 Sysmex Corporation Emulsion systems for emulsion-based amplification of nucleic acid
ES2886507T5 (es) 2012-10-29 2024-11-15 Univ Johns Hopkins Prueba de Papanicolaou para cánceres de ovario y de endometrio
EP2964781B1 (en) 2013-03-08 2018-01-10 Roche Diagnostics GmbH Egfr mutation blood testing
US20140287417A1 (en) 2013-03-08 2014-09-25 Roche Molecular Systems, Inc. EGFR Blood Monitoring
DK2970958T3 (en) 2013-03-15 2018-02-19 Lineage Biosciences Inc METHODS FOR SEQUENCING THE IMMUN REPERTOIR
EP4253558B1 (en) 2013-03-15 2025-07-02 The Board of Trustees of the Leland Stanford Junior University Identification and use of circulating nucleic acid tumor markers
US9116866B2 (en) 2013-08-21 2015-08-25 Seven Bridges Genomics Inc. Methods and systems for detecting sequence variants
US9898575B2 (en) 2013-08-21 2018-02-20 Seven Bridges Genomics Inc. Methods and systems for aligning sequences
WO2015058097A1 (en) 2013-10-18 2015-04-23 Seven Bridges Genomics Inc. Methods and systems for identifying disease-induced mutations
US11049587B2 (en) 2013-10-18 2021-06-29 Seven Bridges Genomics Inc. Methods and systems for aligning sequences in the presence of repeating elements
WO2015058095A1 (en) 2013-10-18 2015-04-23 Seven Bridges Genomics Inc. Methods and systems for quantifying sequence alignment
WO2015058093A1 (en) 2013-10-18 2015-04-23 Seven Bridges Genomics Inc. Methods and systems for genotyping genetic samples
CA2926722A1 (en) * 2013-10-19 2015-04-23 Trovagene, Inc. Detecting mutations in disease over time
US9092402B2 (en) 2013-10-21 2015-07-28 Seven Bridges Genomics Inc. Systems and methods for using paired-end data in directed acyclic structure
EP3378952B1 (en) 2013-12-28 2020-02-05 Guardant Health, Inc. Methods and systems for detecting genetic variants
US9817944B2 (en) 2014-02-11 2017-11-14 Seven Bridges Genomics Inc. Systems and methods for analyzing sequence data
US12492429B2 (en) 2014-04-21 2025-12-09 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
EP3134541B1 (en) 2014-04-21 2020-08-19 Natera, Inc. Detecting copy number variations (cnv) of chromosomal segments in cancer
US20180173846A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
US20160002717A1 (en) * 2014-07-02 2016-01-07 Boreal Genomics, Inc. Determining mutation burden in circulating cell-free nucleic acid and associated risk of disease
US20170211143A1 (en) 2014-07-25 2017-07-27 University Of Washington Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
US12391985B2 (en) 2014-08-07 2025-08-19 Pharmassist Ltd Method of determining PIK3CA mutational status in a sample
PT3198026T (pt) * 2014-08-07 2020-01-16 Pharmassist Ltd Método de determinação do estado mutacional de pik3ca numa amostra
EP3191628B1 (en) 2014-09-12 2022-05-25 The Board of Trustees of the Leland Stanford Junior University Identification and use of circulating nucleic acids
EP4012715B1 (en) 2015-02-10 2025-09-24 The Chinese University Of Hong Kong Detecting mutations for cancer screening and fetal analysis
WO2016141294A1 (en) 2015-03-05 2016-09-09 Seven Bridges Genomics Inc. Systems and methods for genomic pattern analysis
CN104762399A (zh) * 2015-04-17 2015-07-08 上海产业技术研究院 肿瘤循环dna kras突变检测方法
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
WO2017027653A1 (en) 2015-08-11 2017-02-16 The Johns Hopkins University Assaying ovarian cyst fluid
US10793895B2 (en) 2015-08-24 2020-10-06 Seven Bridges Genomics Inc. Systems and methods for epigenetic analysis
US10584380B2 (en) 2015-09-01 2020-03-10 Seven Bridges Genomics Inc. Systems and methods for mitochondrial analysis
US10724110B2 (en) 2015-09-01 2020-07-28 Seven Bridges Genomics Inc. Systems and methods for analyzing viral nucleic acids
US11756655B2 (en) * 2015-10-09 2023-09-12 Guardant Health, Inc. Population based treatment recommender using cell free DNA
US11347704B2 (en) 2015-10-16 2022-05-31 Seven Bridges Genomics Inc. Biological graph or sequence serialization
EP3170903B1 (en) * 2015-11-20 2019-09-18 Qiagen GmbH Method for processing a water-in-oil emulsion
JP2019507585A (ja) 2015-12-17 2019-03-22 ガーダント ヘルス， インコーポレイテッド 無細胞ｄｎａの分析による腫瘍遺伝子コピー数を決定するための方法
US20170199960A1 (en) 2016-01-07 2017-07-13 Seven Bridges Genomics Inc. Systems and methods for adaptive local alignment for graph genomes
US10364468B2 (en) * 2016-01-13 2019-07-30 Seven Bridges Genomics Inc. Systems and methods for analyzing circulating tumor DNA
JP6685138B2 (ja) 2016-01-27 2020-04-22 シスメックス株式会社 核酸増幅の精度管理方法、精度管理用試薬およびその試薬キット
US10262102B2 (en) 2016-02-24 2019-04-16 Seven Bridges Genomics Inc. Systems and methods for genotyping with graph reference
RU2760913C2 (ru) 2016-04-15 2021-12-01 Натера, Инк. Способы выявления рака легкого
US10790044B2 (en) 2016-05-19 2020-09-29 Seven Bridges Genomics Inc. Systems and methods for sequence encoding, storage, and compression
US11289177B2 (en) 2016-08-08 2022-03-29 Seven Bridges Genomics, Inc. Computer method and system of identifying genomic mutations using graph-based local assembly
US11250931B2 (en) 2016-09-01 2022-02-15 Seven Bridges Genomics Inc. Systems and methods for detecting recombination
WO2018067517A1 (en) 2016-10-04 2018-04-12 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
CN114774520B (zh) * 2016-11-17 2025-09-05 阅尔基因技术（苏州）有限公司 检测肿瘤发展的系统和方法
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
MY197535A (en) 2017-01-25 2023-06-21 Univ Hong Kong Chinese Diagnostic applications using nucleic acid fragments
WO2018138539A1 (en) * 2017-01-25 2018-08-02 Qiagen Gmbh Method for processing a water-in-oil emulsion
JP6933907B2 (ja) 2017-02-24 2021-09-08 シスメックス株式会社 核酸増幅方法
US10726110B2 (en) 2017-03-01 2020-07-28 Seven Bridges Genomics, Inc. Watermarking for data security in bioinformatic sequence analysis
US11347844B2 (en) 2017-03-01 2022-05-31 Seven Bridges Genomics, Inc. Data security in bioinformatic sequence analysis
WO2018183942A1 (en) 2017-03-31 2018-10-04 Grail, Inc. Improved library preparation and use thereof for sequencing-based error correction and/or variant identification
US10527608B2 (en) 2017-06-13 2020-01-07 Genetics Research, Llc Methods for rare event detection
US10081829B1 (en) 2017-06-13 2018-09-25 Genetics Research, Llc Detection of targeted sequence regions
US10947599B2 (en) 2017-06-13 2021-03-16 Genetics Research, Llc Tumor mutation burden
CA3069938A1 (en) 2017-06-13 2018-12-20 Genetics Research, Llc, D/B/A Zs Genetics, Inc. Isolation of target nucleic acids
WO2018231967A2 (en) * 2017-06-13 2018-12-20 Genetics Research, Llc, D/B/A Zs Genetics, Inc. Rare nucleic acid detection
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
DK3658684T3 (da) 2017-07-26 2023-10-09 Univ Hong Kong Chinese Forbedring af cancerscreening ved hjælp af cellefrie, virale nukleinsyrer
CN111868260B (zh) 2017-08-07 2025-02-21 约翰斯霍普金斯大学 用于评估和治疗癌症的方法和材料
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
US12046325B2 (en) 2018-02-14 2024-07-23 Seven Bridges Genomics Inc. System and method for sequence identification in reassembly variant calling
WO2019161244A1 (en) 2018-02-15 2019-08-22 Natera, Inc. Methods for isolating nucleic acids with size selection
CN111742058B (zh) * 2018-02-21 2025-11-14 纽克莱克斯有限公司 用于确定从全血分离血浆的效率的方法和试剂盒
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
JP6975350B2 (ja) * 2018-05-03 2021-12-01 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 腫瘍突然変異量の測定のための代理マーカーおよび方法
US11702697B2 (en) * 2018-05-14 2023-07-18 Roche Sequencing Solutions, Inc. Quality testing of DNA samples
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
EP3725894A1 (en) * 2019-04-16 2020-10-21 Blod Diagnostik GmbH Apparatus and methods for nucleic acid target enrichment, suspension and quantification
WO2020247263A1 (en) 2019-06-06 2020-12-10 Natera, Inc. Methods for detecting immune cell dna and monitoring immune system
US20220228221A1 (en) * 2019-06-17 2022-07-21 The Board Of Trustees Of The Leland Stanford Junior University Diagnostics and Treatments Based Upon Molecular Characterization of Colorectal Cancer
JP2023508411A (ja) 2019-12-23 2023-03-02 バイオプセンス オサケユキチュア 血液試料からセルフリー核酸を抽出するための方法、自動化システムおよびカートリッジ
CN115516108A (zh) 2020-02-14 2022-12-23 约翰斯霍普金斯大学 评估核酸的方法和材料
CN111575377B (zh) * 2020-05-19 2024-02-23 邹畅 用于line-1的检测引物组及其应用
WO2022031620A2 (en) * 2020-08-01 2022-02-10 Aigene Methods for the rapid assessment of the efficacy of cancer therapy and related applications
US20220275450A1 (en) * 2021-02-24 2022-09-01 Michael J. Powell Method for conducting early detection of colon cancer and/or of colon cancer precursor cells and for monitoring colon cancer recurrence
AU2022261868A1 (en) * 2021-04-22 2023-10-26 Natera, Inc. Methods for determining velocity of tumor growth
AU2024252845A1 (en) 2023-04-06 2025-10-16 Glaxosmithkline Intellectual Property (No.4) Limited Methods for treating and monitoring cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005522229A (ja) * 2002-04-09 2005-07-28 オックスフォード グライコサイエンシス （ユーケイ） リミテッド 癌に関与する蛋白質
WO2006128192A2 (en) * 2005-05-27 2006-11-30 John Wayne Cancer Institute Use of free circulating dna for diagnosis, prognosis, and treatment of cancer
JP2007277242A (ja) * 2006-04-05 2007-10-25 Pfizer Prod Inc Ｃｔｌａ４抗体併用療法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156504A (en) * 1996-03-15 2000-12-05 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays
US20020120409A1 (en) * 2000-05-19 2002-08-29 Affymetrix, Inc. Methods for gene expression analysis
US20030165940A1 (en) * 2001-12-06 2003-09-04 The Johns Hopkins University Disease detection by digital protein truncation assays
US9109256B2 (en) 2004-10-27 2015-08-18 Esoterix Genetic Laboratories, Llc Method for monitoring disease progression or recurrence
WO2007050465A2 (en) * 2005-10-24 2007-05-03 The Johns Hopkins University Improved methods for beaming
US20100041048A1 (en) * 2008-07-31 2010-02-18 The Johns Hopkins University Circulating Mutant DNA to Assess Tumor Dynamics
US8517508B2 (en) 2009-07-02 2013-08-27 Fujifilm Dimatix, Inc. Positioning jetting assemblies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005522229A (ja) * 2002-04-09 2005-07-28 オックスフォード グライコサイエンシス （ユーケイ） リミテッド 癌に関与する蛋白質
WO2006128192A2 (en) * 2005-05-27 2006-11-30 John Wayne Cancer Institute Use of free circulating dna for diagnosis, prognosis, and treatment of cancer
JP2007277242A (ja) * 2006-04-05 2007-10-25 Pfizer Prod Inc Ｃｔｌａ４抗体併用療法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014007977; Ｇａｓｔｒｏｅｎｔｅｒｏｌｏｇｙ．　２００８　Ａｕｇ（Ｅｐｕｂ　２００８　Ｍａｙ　１５），　Ｖｏｌ．１３５，　Ｎｏ．２，　ｐ．４８９-４９８，４９８ｅ１-４９８ｅ７ *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016104010A (ja) * 2008-07-31 2016-06-09 ザ ジョンズ ホプキンス ユニバーシティー 腫瘍動態を評価するための循環変異型ｄｎａ
WO2016060227A1 (ja) * 2014-10-17 2016-04-21 東洋鋼鈑株式会社 Ｂｃｒ－ａｂｌ阻害剤耐性関連変異の検出方法及びこれを用いたｂｃｒ－ａｂｌ阻害剤耐性を予測するためのデータ取得方法
JP2016077221A (ja) * 2014-10-17 2016-05-16 東洋鋼鈑株式会社 Ｂｃｒ−ａｂｌ阻害剤耐性関連変異の検出方法及びこれを用いたｂｃｒ−ａｂｌ阻害剤耐性を予測するためのデータ取得方法
JP2018522550A (ja) * 2015-06-23 2018-08-16 ナショナル キャンサー センター 導電性高分子を利用したセルフリーｄｎａ検出用構造体およびその用途
US11352616B2 (en) 2015-06-23 2022-06-07 National Cancer Center Nanostructure for detecting cell-free DNA using conductive polymer and the use thereof
WO2017014177A1 (ja) * 2015-07-17 2017-01-26 凸版印刷株式会社 健康状態の評価方法及び抗がん剤に対する長期奏功性の予測方法
JPWO2017014177A1 (ja) * 2015-07-17 2018-04-26 凸版印刷株式会社 健康状態の評価方法及び抗がん剤に対する長期奏功性の予測方法
WO2020026776A1 (ja) 2018-07-31 2020-02-06 学校法人 岩手医科大学 がんの診断のためのプローブ／プライマーライブラリー
KR20210038607A (ko) 2018-07-31 2021-04-07 이와테 메디칼 유니버시티 에듀케이셔널 파운데이션 암의 진단을 위한 프로브/프라이머 라이브러리
US12492433B2 (en) 2018-07-31 2025-12-09 Iwate Medical University Educational Foundation Probe/primer library for diagnosis of cancer
WO2024203348A1 (ja) * 2023-03-31 2024-10-03 ソニーグループ株式会社 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法

Also Published As

Publication number Publication date
US20240002948A1 (en) 2024-01-04
CA2732623C (en) 2018-08-21
US20250313901A1 (en) 2025-10-09
CA2732623A1 (en) 2010-02-04
EP2315849A1 (en) 2011-05-04
WO2010014920A1 (en) 2010-02-04
EP2315849B1 (en) 2017-11-08
US20100041048A1 (en) 2010-02-18
US20200370123A1 (en) 2020-11-26
EP2315849A4 (en) 2012-02-22
JP2016104010A (ja) 2016-06-09

Similar Documents

Publication Publication Date Title
US20250313901A1 (en) Circulating mutant dna to assess tumor dynamics
JP7385630B2 (ja) 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法
US9109256B2 (en) Method for monitoring disease progression or recurrence
JP4808365B2 (ja) Ｐｃｒ法
CA2957396C (en) Method of determining pik3ca mutational status in a sample
Rose et al. Circulating and urinary tumour DNA in urothelial carcinoma—Upper tract, lower tract and metastatic disease
JP2011529691A5 (enExample)
WO2009051842A2 (en) Detection of cancer by measuring genomic copy number and strand length in cell-free dna
US20150072947A1 (en) Gene biomarkers for prediction of susceptibility of ovarian neoplasms and/or prognosis or malignancy of ovarian cancers
JP7665659B2 (ja) 循環腫瘍核酸分子のマルチモーダル分析
JP2010518868A (ja) 前立腺癌の生存及び再発
ES3036448T3 (en) A dna-methylation test for prostate cancer
JP6608424B2 (ja) 前癌性結腸直腸ポリープおよび結腸直腸癌を特定するための方法およびキット
US20250179583A1 (en) Methylated dna markers and assays thereof for use in detecting colorectal cancer
US20080003600A1 (en) Isothermal screening of breast cancer related nucleic acid
US12391985B2 (en) Method of determining PIK3CA mutational status in a sample
JP2011015679A (ja) 黒色腫の早期検出のための方法及び試薬
US20070248546A1 (en) Clinical algorithm for excluding patients identified in virtual imaging
TW202328459A (zh) 一種腫瘤檢測方法及應用
JP2014527816A (ja) 初期卵巣がんの検出マーカーとしての精子タンパク質
KR20220052466A (ko) Braf 유전자 내의 단일염기다형성 마커를 포함하는 대장암 재발 예측용 조성물
KR20220052467A (ko) Egfr 유전자 내의 단일염기다형성 마커를 포함하는 대장암 재발 예측용 조성물
Colin et al. Somatic copy number profiling from hepatocellular carcinoma circulating tumor cells
BR112018013430B1 (pt) Métodos para detectar pelo menos uma mutação em uma pluralidade de genes relacionados a câncer de tireoide, para selecionar um sujeito que tem nódulos na tireoide, e, para prognosticar risco de malignidade

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140530

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150304

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150703

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160115